Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Tempest Therapeutics, Inc. (OVAS)
|
Add to portfolio |
|
|
|
| Price: |
$1.06
| | Metrics |
| OS: |
13.3
|
M
| |
-664
|
% ROE
|
| Market cap: |
$14.1
|
M
| |
-392
|
% ROIC
|
|
Net cash:
|
$7.15
|
M
| |
$0.54
|
per share
|
|
EV:
|
$6.98
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($32.1)
|
M
| |
|
|
|
EBIT
|
($32.8)
|
M
| |
|
|
| EPS |
($2.54)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 90.8 | 53.7 | 0.3 | 0.7 | 0.3 |
| Revenue growth | | | -100.0% | 68.9% | 18119.7% | -54.8% | 135.7% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 5.4 | 2.2 |
| Gross profit | 0.0 | 0.0 | 0.0 | 90.8 | 53.7 | -0.5 | -4.7 | -2.0 |
| Gross margin | | | | 100.0% | 100.0% | -167.8% | -727.1% | -711.9% |
| Selling, general and administrative | | | | | | 27.7 | 49.2 | 51.6 |
| Research and development | 22.5 | 17.2 | 14.4 | 27.8 | 14.4 | 18.3 | 21.6 | 18.4 |
| General and administrative | 12.1 | 9.8 | 4.9 | 17.6 | 8.7 | | | |
| EBIT | -34.6 | -27.0 | -19.3 | 45.4 | 26.9 | -47.6 | -77.2 | -73.6 |
| EBIT margin | | | | 50.0% | 50.0% | -16133.6% | -11815.3% | -26556.0% |
| Pre-tax income | -35.7 | -28.3 | -19.2 | -44.6 | -27.2 | -50.9 | -82.1 | -73.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | 0.1 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | | | | |
| Net income | -35.7 | -28.3 | -19.2 | -44.6 | -27.2 | -51.0 | -82.3 | -73.2 |
| Net margin | | | | -49.1% | -50.6% | -17279.7% | -12597.2% | -26432.9% |
| |
| Diluted EPS | ($3.09) | ($7.47) | ($41.03) | ($3.25) | ($17.58) | ($1.43) | ($2.56) | ($2.70) |
| Shares outstanding (diluted) | 11.5 | 3.8 | 0.5 | 13.7 | 1.5 | 35.7 | 32.1 | 27.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|